Public health leaders warned of an incoming fiscal cliff during the pandemic, when the federal government provided historic cash infusions to states, most of which have expired.

Masimo executives are back calling their consumer audio business Sound United, with a senior executive on a conference call ...

Apple and Masimo’s legal battle over the Apple Watch’s Blood Oxygen sensing feature continues this week as both firms meet in ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

The healthcare sector depends on medical technology advancements, particularly devices used in disease prevention, diagnosis, ...

In the matter of the three design patents, the jury found in Favor of Apple in the case of the D’842 Patent for the Original Design (discontinued models) of the Masimo W1, Freedom, and Health ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Masimo MASI2.83%increase; green up pointing triangle said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been terminated by the company. Kiani’s ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...